Astera Labs director Stefan Dyckerhoff sells $4.7m in shares

On October 7, 2026, Stefan Dyckerhoff, a director at Astera Labs (NASDAQ:ALAB), sold shares worth approximately $4.7 million. The shares were sold at $376.06 each. Since then, the stock has fallen to $342.21, still up 106% year-to-date with a market capitalization of $60.2 billion. According to InvestingPro, the stock appears overvalued relative to its Fair Value.

The transactions included 3,505 direct sales of common shares, 8,333 indirect sales through a trust, and 661 shares sold via a limited partnership. These sales were made under a Rule 10b5-1 trading plan adopted by Dyckerhoff on December 1, 2025. Prior to selling, Dyckerhoff bought 68 shares at $311.57 each on October 1, 2026, totaling about $21,186.

These shares are part of a restricted stock unit award under the company’s 2024 Stock Option and Incentive Plan, to be vested three months after August 15, 2026, upon Dyckerhoff’s continuous service. After these transactions, Dyckerhoff directly holds 47,019 shares and indirectly holds shares through trusts and partnerships. Astera Labs reported strong Q2 2026 earnings, exceeding Wall Street expectations with revenue of $392.4 million, a 104% increase year-over-year, and earnings per share of $0.80, beating the predicted $0.69.

Needham upgraded Astera Labs to a Buy with a price target of $425, citing growth across all product lines. Scorpio X shipments are expected to ramp up in the latter half of 2026, with at least two customers anticipated to place orders this year. Northland upgraded Astera Labs to Outperform from Market Perform, anticipating positive AI infrastructure spending and potential earnings revisions, though they had previously downgraded the company due to valuation concerns.